Towards Healthcare
U.S. Controlled Substance Market to Drive USD 84.95 Bn by 2034

U.S. Controlled Substance Market boosted by online pharmacies

Based on market forecasts, the U.S. Controlled Substance market, projected at USD 52.3 billion in 2024, is expected to reach USD 84.95 billion by 2034, growing at a CAGR of 5.24% over the forecast period. The U.S. Controlled Substance Market is growing because these substances extend throughout manufacture, use, handling, distribution, and storage. This substance offers several advantages, including improved alertness, increased energy, potential support for executive function, and a rapid onset of action.

Content

  • Insight Code: 6168
  • No. of Pages: 150+
  • Format: PDF/PPT/Excel
  • Published: September 2025
  • Report Covered: [Revenue + Volume]
  • Historical Year: 2021-2022
  • Base Year: 2023
  • Estimated Years: 2024-2033

About The Author

Rohan Patil is a seasoned market research professional with over 5 years of focused experience in the healthcare sector, bringing deep domain expertise, strategic foresight, and analytical precision to every project he undertakes.

He began his journey with Precedence Research, where he played a pivotal role in developing high-impact healthcare market reports. Today, Rohan leads research initiatives at Towards Healthcare, while also contributing to Statifacts, where he supports cross-industry analysis and data-driven storytelling.

Rohan’s core strengths lie in trend analysis and emerging technologies, regulatory monitoring and thought leadership through high-quality report writing. He excels at identifying future-ready opportunities and translating complex data into strategic recommendations. His work spans pharmaceuticals, biotechnology, medical devices, and digital health, assessing everything from market potential and competitive positioning to customer needs and regulatory shifts.

A trusted advisor and a relentless innovator, Rohan continues to push the boundaries of traditional market research, merging scientific rigor with commercial insight to stay ahead in a fast-evolving healthcare landscape.

Talk to us
FAQ's

The U.S. controlled substance market currently in 2025 records USD 55 billion and is anticipated to grow to USD 84.95 billion by 2034, advancing at a CAGR of 5.24% from 2024 to 2034.

The U.S. controlled substance market includes three segments by product type, by indication, and by distribution channel.

Some key players include AbbVie, Inc., Pfizer, Inc., Merck & Co., Inc., Mallinckrodt plc, and F. Hoffmann-La Roche AG.

Key trends include the rising focus on pain management and mental health treatments.

Schedule I drugs are the most dangerous drugs of all the drug schedules, with potentially severe psychological or physical dependence.

Ministry of Health and Family Welfare, Government of India, National Institutes of Health, FDA, WHO, PIB, CDC.
Any Questions